Noema Pharma
noemapharma.com
Actively hiring
Rare Disease Therapeutics
Neurology & CNS Therapeutics
Prescription Drugs
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$115.4M
2 rounds on record
Latest round
Series B
Nov 2024 · 22 mo ago
Team
11-50
employees, estimated range
Hiring now
1
open roles
Backers
2
Jeito Capital, Sofinnova Partners
The money's age
Due for its next round
22 months since the last round · hiring slowed
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jan 8, 2025
New executive Noema Pharma Appoints Michael Samar as Chief Financial Officer · noemapharma.com
Nov 12, 2024
Raised a round Series B · FinanzNachrichten.de
Nov 14, 2023
New executive Noema Pharma Appoints Robert Lasser, M.D., as Chief Medical Officer · kdvr.com
Mar 6, 2023
Raised a round Series B $115.4M
2019
Founded
Tractionpublic signals, read monthly
Web presence
top 8%
of 133.2M domains by links, Common Crawl
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Series B | Nov 2024 | — | Forbion, Jeito Capital, Sofinnova Partners, Gilde Healthcare, Polaris | FinanzNachrichten.de |
| Series B | Mar 2023 | $115.4M | — | businesswire.com |
Backed byfrom the funds' portfolios and accelerator catalogs
Jeito Capital 
Sofinnova Partners Similar startupsby what they do, their industry and backers
Minoryx is focused on the discovery and development of novel treatments for severe, orphan diseases of the central nervous system with high…
At Alveus Therapeutics, we are building a differentiated therapeutic portfolio that delivers sustainable weight loss with superior…
Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for…
US FDA Grants Orphan Drug and Rare Pediatric Disease Designations to GEn1E Lifesciences' Dual Signal Modulator for the Treatment of…
Human cells cannot degrade cholesterol, leading to several chronic and orphan diseases. Repair Biotechnologies’ Cholesterol Degrading…
Biossil is an AI native biopharma company based in Toronto. It is advancing late-stage programs in life-threatening indications with urgent…
News
Noema Pharma to Present Phase 2a Results for Cendifensine in Vasomotor Symptoms (Hot Flashes) Due to Menopause at the 2026 ACOG Annual Clinical & Scientific Meeting
Read more
Report
Noema Pharma Announces Phase 2a Study Results with Cendifensine in Women with Vasomotor Symptoms (Hot Flashes) Due to Menopause
Cendifensine demonstrates 92% reduction in number of hot flashesBASEL, Switzerland and BOSTON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Noema Pharma AG today announced positive topline results from a Phase 2a, open-label study evaluating cendifensine in menopaus
Read more
Report
Noema Pharma Announces Phase 2a Study Results with Cendifensine in Women with Vasomotor Symptoms (Hot Flashes) Due to Menopause
Cendifensine demonstrates 92% reduction in number of hot flashes Basel, Switzerland and Boston, MA - November 6, 2025 - Noema Pharma AG today announced positive topline results from a Phase 2a, open-label study evaluating cendifensine in menopausal women
Read more
Report
Noema Pharma Appoints Michael Samar as Chief Financial Officer
Appointment Further Strengthens Leadership Team; Follows Appointment of Volker Knappertz, M.D., as Executive Vice President of Research & Development BASEL, Switzerland, January 8, 2025 (GLOBE NEWSWIRE) - Noema Pharma, a clinical-stage biotech company tar
Read more
Report
Noema Pharma Appoints Volker Knappertz, M.D., as Executive Vice President of Research & Development
BASEL, Switzerland, Dec. 18, 2024 (GLOBE NEWSWIRE) - Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, today announced the appointment of Volker Knappertz, M.D., as Executive Vice President of Re
Read more
Report
Pro access
Upgrade to see all 19 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.
Growth
Hiring Momentum
22/100
Hiring freeze
Open positions
1
0 opened / 1 closed in 30 days
Median time-to-fill
188 days
faster than 11% of the market
ATS activity
Every ~24 hours
09/29/2026
Hiring Dynamics
0%
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Public Policy
100% ▼
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Basel
Switzerland
HQ
10-50 est. staff